As part of the agreement with the DOJ, Pfizer will pay a previously announced $2.3 billion sum ($1.0 billion in civil payments related to a series of drugs and a fine of $1.3 billion that only concerns Bextra), and a subsidiary of Pfizer, Pharmacia & Upjohn Company, Inc. will plead guilty in criminal proceedings, to have violated American food. Drugs and Cosmetics Act in the context of its previous promotion of Bextra. A portion of the civil payments are distributed to 49 states and the District of Columbia, in accordance with agreements with each state`s Medicaid Department. Pfizer had already announced on January 26, 2009, as part of the DOJ agreement, a charge of $ 2.3 billion for its profits in the fourth quarter and for the whole of 2008. As part of this comparison, no additional charges are recognised on the company`s profit. Under the deal, which is the largest ever reached by a drug manufacturer accused of marketing crime, Pfizer will pay $1.0 billion in civil payments related to a series of drugs and a $1.3 billion fine, which only affects Bextra. Pfizer`s current compliance program includes a dedicated Chief Officer, a Corporate Compliance Committee, a Code of Conduct, extensive compliance training, policies and procedures for the successful application of Pfizer products, audits and monitoring, a compliance hotline, and extensive procedures for investigating and resolving potential issues in the event of non-compliance with company guidelines or applicable legal requirements. According to the CIA, Pfizer will use an Independent Review Organization (IRO) that will help the company evaluate and evaluate its advertising and product functions. In addition, a subsidiary of Pfizer, Pharmacia & Upjohn Company, Inc., will plead guilty to violating the United States in criminal proceedings. Food, Drug, and Cosmetic Act as part of its previous promotion of Bextra. A portion of the civil payments are distributed to 49 states and DC, in accordance with Medicare`s public agreements. Pfizer`s disclosure of payment information is subject to the confidentiality rules contained in clinical research agreements entered into prior to July 1, 2009 with a physician established in the United States.

Pfizer will not include these confidentiality clauses in new or renewed clinical research agreements entered into after the CIA`s effective date and which require payment to a United States. . . .